William Kyle, DO
Internal Medicine · Okatie, SCNPI 1770758351
Payments from drug & device makers
Across 108 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$358
- Novo Nordisk$305
- Amgen$234
- Lilly USA, LLC$182
- AstraZeneca$145
- Boehringer Ingelheim$98
- plus $694 from 20 others
What the payments were for
- Food & beverage$2,017100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 18 | $358 |
| Novo Nordisk | 19 | $305 |
| Amgen | 12 | $234 |
| Lilly USA, LLC | 11 | $182 |
| AstraZeneca | 8 | $145 |
| Boehringer Ingelheim | 5 | $98 |
| Boston Scientific | 4 | $97 |
| Exact Sciences | 5 | $76 |
| Sanofi-aventis U.S. LLC | 2 | $61 |
| Kowa Pharmaceuticals America, Inc. | 4 | $47 |
| Abbott | 2 | $43 |
| Astellas Pharma US Inc | 2 | $40 |
| Actelion Pharmaceuticals US, Inc. | 1 | $35 |
| Inspire Medical Systems, Inc. | 2 | $35 |
| Eisai Inc. | 1 | $33 |
| Corcept Therapeutics | 1 | $33 |
| GSK | 2 | $31 |
| AbbVie | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Novartis | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Bayer | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
How this compares
$2,017 in reported general payments places this provider in the 75th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 116 | $148,026 |
| MounjaroTirzepatide | 116 | $140,252 |
| OzempicSemaglutide | 95 | $127,297 |
| JardianceEmpagliflozin | 82 | $117,559 |
| FarxigaDapagliflozin Propanediol | 69 | $91,960 |
| TrulicityDulaglutide | 52 | $71,383 |
| JanuviaSitagliptin Phosphate | 50 | $67,167 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $51,070 |
| TradjentaLinagliptin | 36 | $38,802 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 31 | $31,501 |
| LinzessLinaclotide | 17 | $21,352 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $20,209 |
| MyrbetriqMirabegron | 14 | $18,953 |
| Rosuvastatin Calcium | 1,236 | $14,357 |
| Atorvastatin Calcium | 1,408 | $11,687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $182 | $211,635168 claims |
| Boehringer IngelheimJardiance, Tradjenta | $98 | $156,361118 claims |
| PfizerEliquis, Premarin | $358 | $155,702132 claims |
| Novo NordiskOzempic | $305 | $127,29795 claims |
| AstraZenecaFarxiga | $145 | $91,96069 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $61 | $31,50131 claims |
| AbbVieLinzess, Synthroid | $25 | $30,872211 claims |
| GSKTrelegy Ellipta | $31 | $20,20912 claims |
| Astellas Pharma US IncMyrbetriq | $40 | $18,95314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Okatie
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl SofleyAnderson$673K
- Carl MitchellColumbia$564K
- Jerry BackNorth Charleston$322K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.